Quinolines

Exelixis to Release Second Quarter 2021 Financial Results on Thursday, August 5, 2021

Retrieved on: 
Thursday, July 22, 2021
Oncology, Health, Genetics, Clinical trials, Pharmaceutical, Biotechnology, Chemical compounds, Organic compounds, Orphan drugs, Drugs, Tyrosine kinase inhibitors, Cyclopropanes, Quinolines, Cabozantinib, Exelixis, Cobimetinib, NASDAQ, Daiichi Sankyo

Exelixis, Inc. (Nasdaq: EXEL) announced today that its second quarter 2021 financial results will be released on Thursday, August 5, 2021 after the markets close.

Key Points: 
  • Exelixis, Inc. (Nasdaq: EXEL) announced today that its second quarter 2021 financial results will be released on Thursday, August 5, 2021 after the markets close.
  • At 5:00 p.m. EDT / 2:00 p.m. PDT, Exelixis management will host a conference call and webcast to discuss the results and provide a general business update.
  • For more information about Exelixis, please visit www.exelixis.com , follow @ExelixisInc on Twitter or like Exelixis, Inc. on Facebook.
  • Exelixis, the Exelixis logo, CABOMETYX, COMETRIQ and COTELLIC are registered trademarks of Exelixis, Inc. MINNEBRO is a registered trademark of Daiichi Sankyo Company, Limited.

Exelixis to Present at the Virtual William Blair Biotech Focus Conference on July 15, 2021

Retrieved on: 
Thursday, July 8, 2021
Oncology, Health, Other Health, General Health, Pharmaceutical, Biotechnology, Chemical compounds, Organic compounds, Orphan drugs, Drugs, Tyrosine kinase inhibitors, Exelixis, Cyclopropanes, Quinolines, Cabozantinib, Cobimetinib, Daiichi Sankyo, NASDAQ

Exelixis, Inc. (Nasdaq: EXEL) today announced that Peter Lamb, Ph.D., the companys Executive Vice President, Scientific Strategy and Chief Scientific Officer, will present at the virtual William Blair Biotech Focus Conference 2021 on Thursday, July 15th at 2:00 p.m. EDT / 1:00 p.m. CDT / 11:00 a.m. PDT.

Key Points: 
  • Exelixis, Inc. (Nasdaq: EXEL) today announced that Peter Lamb, Ph.D., the companys Executive Vice President, Scientific Strategy and Chief Scientific Officer, will present at the virtual William Blair Biotech Focus Conference 2021 on Thursday, July 15th at 2:00 p.m. EDT / 1:00 p.m. CDT / 11:00 a.m. PDT.
  • Exelixis is a member of the Standard & Poors (S&P) MidCap 400 index, which measures the performance of profitable mid-sized companies.
  • For more information about Exelixis, please visit www.exelixis.com , follow @ExelixisInc on Twitter or like Exelixis, Inc. on Facebook.
  • Exelixis, the Exelixis logo, CABOMETYX, COMETRIQ and COTELLIC are registered trademarks of Exelixis, Inc. MINNEBRO is a registered trademark of Daiichi Sankyo Company, Limited.

Exelixis and Ipsen Announce Cabozantinib in Combination with an Immune Checkpoint Inhibitor Significantly Improved Progression-Free Survival in Phase 3 COSMIC-312 Pivotal Trial in Patients with Previously Untreated Advanced Liver Cancer

Retrieved on: 
Monday, June 28, 2021
Biotechnology, Health, Pharmaceutical, Clinical trials, Oncology, Chemical compounds, Orphan drugs, Drugs, Organic compounds, Antineoplastic drugs, Tyrosine kinase inhibitors, Cabozantinib, Cyclopropanes, Quinolines, Exelixis, Ipsen, Sorafenib, COSMIC-312, HCC, CABOMETYX® (cabozantinib), Ipsen, COSMIC-312, HCC, CABOMETYX® (CABOZANTINIB), IPSEN

Patients were randomized approximately 2:1:1 to one of three arms: cabozantinib (40 mg) in combination with atezolizumab, sorafenib, or cabozantinib (60 mg).

Key Points: 
  • Patients were randomized approximately 2:1:1 to one of three arms: cabozantinib (40 mg) in combination with atezolizumab, sorafenib, or cabozantinib (60 mg).
  • In the European Union, CABOMETYX is also approved in combination with nivolumab as first line treatment for patients living with advanced RCC.
  • In 2016, Exelixis granted Ipsen exclusive rights for the commercialization and further clinical development of cabozantinib outside of the United States and Japan.
  • The incidence of Grade 3 to 5 hemorrhagic events was 5% in CABOMETYX patients in RCC and HCC studies.

Exelixis and Ipsen Announce Cabozantinib in Combination with an Immune Checkpoint Inhibitor Significantly Improved Progression-Free Survival in Phase 3 COSMIC-312 Pivotal Trial in Patients with Previously Untreated Advanced Liver Cancer

Retrieved on: 
Monday, June 28, 2021
Research, FDA, Clinical trials, Other Health, General Health, Pharmaceutical, Health, Science, Oncology, Other Science, Chemical compounds, Orphan drugs, Drugs, Organic compounds, Antineoplastic drugs, Tyrosine kinase inhibitors, Cabozantinib, Cyclopropanes, Quinolines, Exelixis, Ipsen, Sorafenib, COSMIC-312, HCC, CABOMETYX® (cabozantinib), Ipsen, COSMIC-312, HCC, CABOMETYX® (CABOZANTINIB), IPSEN

Patients were randomized approximately 2:1:1 to one of three arms: cabozantinib (40 mg) in combination with atezolizumab, sorafenib, or cabozantinib (60 mg).

Key Points: 
  • Patients were randomized approximately 2:1:1 to one of three arms: cabozantinib (40 mg) in combination with atezolizumab, sorafenib, or cabozantinib (60 mg).
  • In the European Union, CABOMETYX is also approved in combination with nivolumab as first line treatment for patients living with advanced RCC.
  • In 2016, Exelixis granted Ipsen exclusive rights for the commercialization and further clinical development of cabozantinib outside of the United States and Japan.
  • The incidence of Grade 3 to 5 hemorrhagic events was 5% in CABOMETYX patients in RCC and HCC studies.

Exelixis and Ipsen Announce Detailed Results from Phase 3 COSMIC-311 Pivotal Trial of Cabozantinib in Patients with Previously Treated Radioactive Iodine-Refractory Differentiated Thyroid Cancer Presented at ASCO 2021

Retrieved on: 
Monday, June 7, 2021
Biotechnology, Pharmaceutical, Health, Oncology, Anatomy, Thyroid disease, Organ systems, Cyclopropanes, Orphan drugs, Organs anatomy), Cabozantinib, Quinolines, Exelixis, Thyroid cancer, Ipsen, Thyroid nodule, CABOMETYX, CABOMETYX

Exelixis, Inc. (NASDAQ: EXEL) and Ipsen (Euronext:IPN; ADR:IPSEY) today announced detailed results from the phase 3 COSMIC-311 pivotal trial of cabozantinib (CABOMETYX) in patients with previously treated radioactive iodine-refractory differentiated thyroid cancer (DTC).

Key Points: 
  • Exelixis, Inc. (NASDAQ: EXEL) and Ipsen (Euronext:IPN; ADR:IPSEY) today announced detailed results from the phase 3 COSMIC-311 pivotal trial of cabozantinib (CABOMETYX) in patients with previously treated radioactive iodine-refractory differentiated thyroid cancer (DTC).
  • COSMIC-311 is a global, multicenter, randomized, double-blind, placebo-controlled phase 3 pivotal trial that aimed to enroll approximately 300 patients at 150 sites globally.
  • In 2016, Exelixis granted Ipsen exclusive rights for the commercialization and further clinical development of cabozantinib outside of the United States and Japan.
  • Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer: The American Thyroid Association (ATA) Guidelines Taskforce on Thyroid Nodules and Differentiated Thyroid Cancer.

Final Data from Calithera Biosciences’ Phase 2 CANTATA Study in Renal Cell Carcinoma Presented at 2021 ASCO Annual Meeting

Retrieved on: 
Monday, June 7, 2021
Tyrosine kinase inhibitors, Cabozantinib, Cyclopropanes, Quinolines, Medicine, Progression-free survival, Chemical substances, Health care

The findings were highlighted in an oral presentation at the virtual American Society of Clinical Oncology (ASCO) 2021 Annual Meeting.

Key Points: 
  • The findings were highlighted in an oral presentation at the virtual American Society of Clinical Oncology (ASCO) 2021 Annual Meeting.
  • Results announced previously showed that the addition of telaglenastat to cabozantinib did not improve progression-free survival (PFS) in the study population.
  • Median progression-free survival (mPFS) in patients who received telaglenastat and cabozantinib was 9.2 months versus 9.3 months in patients who received placebo and cabozantinib.
  • The frequency and severity of adverse events in the telaglenastat-treated population were comparable to those of cabozantinib alone and remained consistent with known risks of both agents.

Exelixis and Ipsen Announce Detailed Results from Phase 3 COSMIC-311 Pivotal Trial of Cabozantinib in Patients with Previously Treated Radioactive Iodine-Refractory Differentiated Thyroid Cancer Presented at ASCO 2021

Retrieved on: 
Monday, June 7, 2021
Biotechnology, Health, Pharmaceutical, Clinical trials, Oncology, Anatomy, Thyroid disease, Organ systems, Cyclopropanes, Orphan drugs, Organs anatomy), Cabozantinib, Quinolines, Exelixis, Thyroid cancer, Ipsen, Thyroid nodule, CABOMETYX, CABOMETYX

Exelixis, Inc. (NASDAQ: EXEL) and Ipsen (Euronext:IPN; ADR:IPSEY) today announced detailed results from the phase 3 COSMIC-311 pivotal trial of cabozantinib (CABOMETYX) in patients with previously treated radioactive iodine-refractory differentiated thyroid cancer (DTC).

Key Points: 
  • Exelixis, Inc. (NASDAQ: EXEL) and Ipsen (Euronext:IPN; ADR:IPSEY) today announced detailed results from the phase 3 COSMIC-311 pivotal trial of cabozantinib (CABOMETYX) in patients with previously treated radioactive iodine-refractory differentiated thyroid cancer (DTC).
  • COSMIC-311 is a global, multicenter, randomized, double-blind, placebo-controlled phase 3 pivotal trial that aimed to enroll approximately 300 patients at 150 sites globally.
  • In 2016, Exelixis granted Ipsen exclusive rights for the commercialization and further clinical development of cabozantinib outside of the United States and Japan.
  • Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer: The American Thyroid Association (ATA) Guidelines Taskforce on Thyroid Nodules and Differentiated Thyroid Cancer.

Exelixis Announces Quality-Adjusted Survival Benefit Demonstrated in Analysis of Phase 3 CheckMate -9ER Trial of CABOMETYX® (cabozantinib) in Combination with OPDIVO® (nivolumab) in Patients with Previously Untreated Advanced Renal Cell Carcinoma

Retrieved on: 
Friday, June 4, 2021
General Health, Health, Pharmaceutical, Clinical trials, Oncology, Chemical compounds, Drugs, Cancer treatments, Antineoplastic drugs, Orphan drugs, Cabozantinib, Cyclopropanes, Quinolines, Sunitinib, Renal cell carcinoma, Nivolumab, Toni Choueiri, CheckMate -9ER, RCC, CABOMETYX® (cabozantinib), Exelixis, CHECKMATE -9ER, RCC, CABOMETYX® (CABOZANTINIB), EXELIXIS

This analysis shows that the overall survival benefit demonstrated in the phase 3 CheckMate -9ER trial results in clinically important gains in quality-adjusted survival.

Key Points: 
  • This analysis shows that the overall survival benefit demonstrated in the phase 3 CheckMate -9ER trial results in clinically important gains in quality-adjusted survival.
  • CheckMate -9ER is an open-label, randomized (1:1), multi-national phase 3 trial evaluating patients with previously untreated advanced or metastatic renal cell carcinoma with a clear cell component.
  • The primary efficacy analysis compares the doublet combination regimen of CABOMETYX and OPDIVO versus sunitinib in all randomized patients.
  • The incidence of Grade 3 to 5 hemorrhagic events was 5% in CABOMETYX patients in RCC and HCC studies.

Yingli Pharma Announces presentations on the Phase 1 trials of linperlisib, a PI3Kδ selective inhibitor, and YL-13027, an oral TGFβR1 inhibitor, at the American Society for Clinical Oncology 2021 Annual Meeting

Retrieved on: 
Friday, June 4, 2021
Branches of biology, Signal transduction, Clinical medicine, Medicine, Oncology, Drug discovery, Phosphoinositide 3-kinase inhibitor, Phosphoinositide 3-kinase, MTOR, Antineoplastic drugs, Quinolines, Dactolisib

Globally, there are no PI3K inhibitors that have been approved for the treatment of T cell lymphomas.

Key Points: 
  • Globally, there are no PI3K inhibitors that have been approved for the treatment of T cell lymphomas.
  • Another clinical study of linperlisib was also presented at ASCO entitled "A phase Ib study of the PI3K inhibitor linperlisib in patients with advanced solid tumors".
  • "YL-13027 has demonstrated to be a safe and tolerable oral agent that is highly selective for TGFR1 over TGFR2.
  • Yingli Pharma is developing best-in-class and first-in-class oral investigational agents for the treatment of cancer, metabolic and autoimmune diseases.

Exelixis Announces Phase 1b Results from Cohort 6 of COSMIC-021 Trial in Patients with Metastatic Castration-Resistant Prostate Cancer

Retrieved on: 
Monday, May 24, 2021
Oncology, Health, General Health, Radiology, Clinical trials, Pharmaceutical, Biotechnology, Orphan drugs, Chemical compounds, Drugs, Cancer treatments, Cabozantinib, Cyclopropanes, Quinolines, Exelixis, Prostate cancer, Atezolizumab, CRPC, Nicholas J. Vogelzang, the COSMIC-021 Study, CRPC, CABOMETYX® (cabozantinib), Exelixis, THE COSMIC-021 STUDY, CRPC, CABOMETYX® (CABOZANTINIB), EXELIXIS

Exelixis, Inc. (NASDAQ: EXEL) today announced results from the metastatic castration-resistant prostate cancer (CRPC) cohort 6 of COSMIC-021, the phase 1b trial of cabozantinib (CABOMETYX) in combination with atezolizumab in patients with locally advanced or metastatic solid tumors.

Key Points: 
  • Exelixis, Inc. (NASDAQ: EXEL) today announced results from the metastatic castration-resistant prostate cancer (CRPC) cohort 6 of COSMIC-021, the phase 1b trial of cabozantinib (CABOMETYX) in combination with atezolizumab in patients with locally advanced or metastatic solid tumors.
  • Many patients with metastatic castration-resistant prostate cancer who have progressed on a novel hormonal therapy wish to avoid or delay chemotherapy.
  • We look forward to building on these results with the phase 3 CONTACT-02 trial in our continued effort to bring cabozantinib to many more patients in need.
  • COSMIC-021 is a multicenter, phase 1b, open-label study that is divided into two parts: a dose-escalation phase and an expansion cohort phase.